Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ-0,37
KB998,5-3,25
PKN140,72141,26-1,87
Msft535,14535,44-3,65
Nokia6,756,774-7,26
IBM247,21247,3-2,78
Mercedes-Benz Group AG42,67542,7851,38
PFE29,8929,9-2,89
05.11.2026 22:00:01
Indexy online
AD Index online
select
AD Index online
 

Malin Corp
Poslední obchod Změna (%) Změna Objem obchodů ()
- - -
Poslední obchod Změna (%) Změna Objem obchodů ()
- - -
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace:
Popis společnosti
Obecné informace
Název společnostiMalin Corporation plc
TickerMLC
Kmenové akcie:Ordinary Shares
Kmenové akcie:Ordinary Shares
RICMLCM.I
ISINIE00BVGC3741
Poslední známé roční výsledky31.12.2017
Poslední známé čtvrtletní výsledky30.06.2018
Počet zaměstnanců k 31.12.2017 302
Akcie v oběhu k 30.06.2018 48 805 950
MěnaEUR
Kontaktní informace
UliceDun Laoghaire, 2 Harbour Road
MěstoDUBLIN
PSČ 
ZeměIreland
Kontatní osoba 
Funkce kontaktní osoby 
Telefon35 319 015 700
Fax35319015701

Business Summary: Malin Corporation plc is an Ireland-based global life sciences company. The Company's businesses include 3D4Medical, which is a technology company; Altan, which is an injectable drug company; AN2H Discovery Limited, which focuses on designing novel small molecule therapeutics; Emba Medical Limited, which offers vascular embolization system; Emba Neuro Limited; Hatteras Venture Partners (HVP), which is a life sciences company; Immunocore, which is a biotechnology company; Jaan Health, which is a healthcare mobile technology company; Kymab Limited, which is a biopharmaceutical company; Melinta Therapeutics, Inc.; Novan, Inc., which is a clinical stage company; Poseida Therapeutics, Inc., which is a human therapeutics company, and Viamet Pharmaceuticals, Inc., which is a drug discovery company. The Company operates through subsidiaries, and focuses on various therapeutic areas, including dermatology, anti-infective, pain, immunology, oncology, neurology, anatomy and other areas.
Financial Summary: BRIEF: For the six months ended 30 June 2018, Malin Corporation plc revenues increased 4% to EUR22.5M. Net loss decreased 16% to EUR22.5M. Revenues reflect Rest of world segment increase from EUR1.8M to EUR5.3M, Spain segment increase of 4% to EUR12.4M. Lower net loss reflects Equity Earnings -Before increase from EUR5.6M (expense) to EUR7.5M (income), Equity Earnings -Before Taxes decrease of 91% to EUR1.2M (expense).
Odvětvová klasifikace
TRBC2012Pharmaceuticals - NEC
RBSS2004Pharmaceuticals - Generic & Specialty
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
SICPharmaceutical Preparations
SICCommercial Physical Research



  • Poslední aktualizace:
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Interim Executive Chairman of the BoardIan Curley5526.10.201826.10.2018
Chief Executive Officer, DirectorBahija Jallal5607.01.201907.01.2019
Chief Financial Officer, Executive DirectorDarragh Lyons35
General Counsel, Company SecretaryNeil McLoughlin-
Senior AnalystDavid Dobrosky-
Head of Tax and Corporate AffairsFiona Dunlevy-
Member of Senior Management TeamPeter Schwartzman-07.10.201607.10.2016